Immunicum AB (Immunicum)

Oncology Corporate Profile

HQ Location

Grafiska v?_gen 2
SE-412 63
Gothenburg, Sweden,

Company Description

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Since the raw material consists of allogeneic dendritic cells, Immunicum's products can be produced in large scale. The vaccines are now undergoing clinical trials in renal cell carcinoma and hepatocellular carcinoma.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ilixadencelimmunotherapyRenal cell carcinoma (RCC)II
ilixadencelimmunotherapyHepatocellular carcinoma (HCC)I

View additional information on product candidates here »


Recent News Headlines

There are no news items to display